LONDON, 9 August 2007 – Hikma Pharmaceuticals PLC (”Hikma”)(LSE: HIK)(DIFX: HIK), the multinational pharmaceuticals group, announces that it has agreed to acquire the entire issued share capital of Alkan Pharma (”Alkan”)(the “Company”), an Egyptian pharmaceuticals company, for a cash consideration of $60.5 million (EGP 342 million). The acquisition is scheduled to complete in the second half of 2007, subject to meeting certain regulatory requirements. The acquisition will be funded entirely by debt.
